[2-Amino-2-(hydroxymethyl)-4-(4-octylphenyl)butyl]phosphonic acid

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: [2-Amino-2-(hydroxymethyl)-4-(4-octylphenyl)butyl]phosphonic acid
• 英文别名: [2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butyl]phosphonic acid
• 化学式: C₁₉H₃₄NO₄P
• 分子量: 371.5
• InChiKey: SNRQRHAFIRNPPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  25
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  104
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• ENHANCEMENT OF CHEMOTHERAPY EFFICIENCY BY SPHINGOSINE-1-PHOSPHATE
  申请人：AC BioScience

  公开号：EP3443986A1

  公开（公告）日：2019-02-20

  The present invention relates to neoadjuvant prior to chemotherapy. The present invention relates to sphingosine-1-phosphate pathway activator for use in the treatment of cancer as neoadjuvant prior to chemotherapy selected from sphingosine-1-phosphate, sphingosine-1-phosphate lyase inhibitor, sphingosine-1-phospahte receptor agonist and sphingosine kinase activator. The sphingosine-1-phosphate pathway activator enhances the chemotherapy efficiency through the normalization of intratumoral vascular network, promoting the effects of the sequential administration of an anticancer agent.

  本发明涉及化疗前的新辅助治疗。 本发明涉及选自鞘磷脂-1-磷酸、鞘磷脂-1-磷酸裂解酶抑制剂、鞘磷脂-1-磷酸受体激动剂和鞘磷脂激酶激活剂的用于治疗癌症的鞘磷脂-1-磷酸途径激活剂，作为化疗前的新辅助剂。 鞘氨醇-1-磷酸途径激活剂通过使瘤内血管网络正常化来提高化疗效率，促进抗癌剂连续给药的效果。
• ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY
  申请人：AC BioScience

  公开号：EP3668506A1

  公开（公告）日：2020-06-24
• COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US20140193376A1

  公开（公告）日：2014-07-10

  The present embodiments provide for combinations of modulators that increase hematopoietic stem cell engraftment or increase mobilization in vivo. Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells (HSCs) from the bone marrow to the peripheral blood are disclosed. One aspect of the invention relates to the use of a CXCR4 antagonist that act in concert with specific molar ratios of S1P receptor 1 (S1PR1) modulator agents to promote HSC mobilization. The invention also relates to methods of using these combinations of CXCR4 antagonists and S1PR1 modulator agents for enhancing the mobilization of hematopoietic stem cells when harvesting of the stem cells, for example for the treatment of diseases, disabilities or conditions whereby transplantation of such cells would be beneficial in ameliorating a symptom associated with such diseases, disabilities or conditions. Another aspect of the invention relates to the use of a CXCR4 antagonist that act in concert with different, but specific molar ratios of S1P receptor 1 (S1PR1) modulator agents to promote HSC engraftment and methods for promoting HSC engraftment in a subject in need thereof, e.g., a recipient subject of a bone marrow or HSC transplant. Methods of screening for novel agents and pharmaceutical compositions comprising these agents are also disclosed.
• US9763980B2
  申请人：——

  公开号：US9763980B2

  公开（公告）日：2017-09-19
• [EN] ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY<br/>[FR] AMÉLIORATION DE L'EFFICACITÉ DE TRAITEMENT DU CANCER PAR L'INTERMÉDIAIRE DE LA VOIE SPHINGOSINE-1-PHOSPHATE
  申请人：AC BIOSCIENCE

  公开号：WO2019034768A1

  公开（公告）日：2019-02-21

  The present invention relates to neoadjuvant prior to chemotherapy. The present invention relates to sphingosine-1-phosphate pathway activator for use in the treatment of cancer as neoadjuvant prior to chemotherapy selected from sphingosine-1-phosphate lyase inhibitors. The sphingosine-1-phosphate pathway activator enhances the chemotherapy efficiency through the normalization of intratumoral vascular network, promoting the effects of the sequential administration of an anticancer agent or a sequential radiotherapy.